Clinical Management of HIV
- FREE
- English
- Interdisciplinary
What is the course about?
The course will provide clinicians with an in-depth understanding of the scope and manifestations of HIV-related diseases, their prevention, management, and care. Special emphasis will be placed on co-infections and co-morbidities as well as the latest research findings and guidelines related to HIV treatment. The course will be comprised of 4 sections, with various sub-topics under each section.
The course language is English. We will provide subtitles in English and Russian.
Информация на русском находится внизу страницы.
What will I learn?
By the end of this course, students will be able to:
- differentiate the clinical manifestations of HIV-related diseases
- propose relevant diagnosis, monitoring, and treatment strategies for HIV infection and related diseases according to EACS and WHO guidelines
- recognise benefits and adverse effects of various HIV drug therapies
- assess strategies for prevention and treatment of opioid drug use
- assess strategies for prevention of the transmission of HIV and related infections
- understand public health approaches in delivering HIV/AIDS treatment and strategic use of ARVs for treating and preventing HIV infection
What do I need to know?
Participants should have a basic background in medicine.
Course Structure
The course consists of 4 sections:
Section 1. HIV Epidemiology, Key Populations and Continuum of HIV Care
• Epidemiology of HIV; Surveillance of HIV;
• HIV Services for Hard-to Reach Populations, HIV Harm Reduction and Opioid Substitution; Special Issues with HIV: MSM & Other Risk Groups;
• Continuum of HIV Care, Testing and linkage to care; Retention in HIV Care & Adherence, ART Coverage; Regimens for Procurement
Section 2. Opportunistic Infections
• HIV and the management of Immune Reconstitution Inflammatory Syndrome (IRIS), HIV-related Pulmonary Infections, Central Nervous System & HIV, Central nervous System & HIV-related Opportunistic Infections, Tuberculosis and HIV Co-Infection, Hepatitis C and HIV Co-Infection, Epidemiology of cancers and HIV, Clinical Management of Cancers and HIV, CVD/CKD/Endocrinology,
Section 3. ART - Antiretroviral Treatment
• When to start ART, Which ART to start, How to change ART, Adverse Effects & Monitoring of ART, Adherence &Prevention of HIV Drug Resistance
Section 4. Prevention of HIV
• HIV Prevention, Treatment as Prevention, PrEP
• The principles of PrEP, Studies supporting the use of oral PrEP, Key populations for PrEP, How to prescribe PrEP, Monitoring of PrEP, Adherence to PrEP, Sexual Health and Harm Reduction, How to Diagnose and Manage HIV Seroconversion, Country example UK and France, Engagement of Community and Key Stakeholders, Demonstration projects: Belgium and the Netherlands, Impact on the HIV Epidemic
Course options
Audit Track (for free)
No special requirements.
Audit track with Statement of Participation (29 €)
For obtaining your Statement of Participation in the Audit Track, you need to gain progress by watching the video lectures and quizzes and pay the fee.
This course is, unusual to other courses, that you might know from iversity, divided into sections. Sections let you personalise your learning experience. You can select and then finish those course sections that are the most useful for you instead of doing the whole course from the beginning to the end. Finish the first section and download your first version of your Statement of Participation. An updated version will be available after each section you finish.
Подробнее о курсе
Курс предоставит врачам полное понимание масштабов и проявлений болезней, связанных с ВИЧ, методов их предотвращения, лечения и сопровождения, с особенным акцентом на коинфекции и сопутствующие заболевания. Участники также познакомятся с результатами последних исследований и рекомендациям по лечению ВИЧ. Курс состоит из 4 разделов, каждый из которых включает в себя несколько разных подтем.
Курс проводится на английском с русскими и английскими субтитрами.
Какие знания вы получите?
По окончанию курса, участники смогут:
• распознавать клинические симптомы заболеваний, связанных с ВИЧ
• предлагать подходящий диагноз, мониторинг и стратегию лечения ВИЧ-инфекции и сопутствующих заболеваний, в соответствии с рекомендациями EACS и ВОЗ
• распознавать преимущества и побочные эффекты различных методов лечения ВИЧ
• оценивать стратегии профилактики и лечения употребления опиоидных наркотиков
• оценивать стратегии профилактики передачи ВИЧ и сопутствующих инфекций
• понимать подходы общественного здравоохранения к лечению ВИЧ/СПИД и стратегическое использование АРТ для лечения и профилактики ВИЧ-инфекции.
Что вы должны знать?
Участники должны иметь базовые знания в области медицины.
Структура курса
Курс состоит из 4 разделов:
Раздел 1. Эпидемиология ВИЧ, ключевые группы населения и непрерывность лечения ВИЧ
• Эпидемиология ВИЧ, эпидемиологический надзор за ВИЧ-инфекцией;
• ВИЧ-услуги для труднодоступных групп населения, ВИЧ-программы снижение вреда и опиоидной заместительной терапии; специфические проблемы с ВИЧ: МСМ и другие группы риска;
• Непрерывность лечения ВИЧ, тестирование и увязывание с лечением; приверженность лечению ВИЧ; охват АРТ; схемы закупок.
Раздел 2. Оппортунистические инфекции
• ВИЧ и синдром иммунного восстановления (IRIS или ВСВИ); инфекции легких связанные с ВИЧ; центральная нервная система и ВИЧ; ЦНС и оппортунистические инфекции, связанные с ВИЧ; туберкулез и коинфекция ВИЧ; гепатит C и коинфекция ВИЧ; эпидемиология раковых заболеваний и ВИЧ; клиническое ведение раковых заболеваний и ВИЧ; сердечно-сосудистые заболевания(CVD)/хронические заболевания почек(CKD)/эндокринология.
Раздел 3. АРТ – антиретровирусная терапия
• Начало АРТ; выбор АРТ; замена АРТ; побочные действия и мониторинг АРТ; приверженность и предотвращение резистентности к ВИЧ-препаратам.
Раздел 4. Профилактика ВИЧ
• Профилактика ВИЧ; лечение в качестве профилактики; ДКП (PrEP).
• Принципы ДКП (PrEP); исследования в поддержку использования пероральной ДКП (PrEP); ключевые группы населения для ДКП (PrEP); как назначать ДКП (PrEP); приверженность к ДКП (PrEP); сексуальное здоровье и снижение вреда; диагностика и лечение сероконверсии ВИЧ; примеры из других стран (Великобритания и Франция); вовлечение общественности и ключевых учреждений; демонстрационные проекты: Бельгия и Нидерланды; воздействие на эпидемию ВИЧ.
Course instructors
Manuel Battegay
As a clinician and clinical researcher, Prof. Manuel Battegay has been active in the field of HIV/AIDS since 1988. He is particularly interested in the clinical course of HIV, namely the optimisation of the response to therapy and immune reconstitution as well as on psychosocial issues. Since 1994, he has been a board member of the Swiss HIV Cohort Study Group and chaired the Scientific Board from 1998-2002. Since 2006, he has been a member of the Governing Board of the European AIDS Clinical Society (EACS). He became President of the Society in 2012 after acting as vice-president for four years. He was co-chair of the 14th and 15th EACS Conferences in Brussels in 2013 and Barcelona in 2015, respectively. He is a faculty member of International Antiviral Society-USA and member of the scientific committee of the biennial Glasgow International Congress on Drug Therapy in HIV Infection. Along with the Swiss Tropical and Public Health Institute, he actively participated in upbuilding a large rural HIV Clinic at the St. Francis Referral Hospital in Ifakara, Tanzania.
His current research focuses on improving the response to antiviral therapy, specifically immune reconstitution and aspects related directly to HIV antiviral therapy and other topics in Infectious Diseases.
Prof Jens Lundgren
Prof. Lundgren has more than 20 years of expertise in leading large international research related to infectious complications in HIV-positive persons and transplant recipients funded by the European Commission (EuroSIDA in EuroCoord), the European Medicines Agency (D:A:D) and NIH (INSIGHT studies). He is the lead of the European-funded networks and co-founder of the global infectious disease research network INSIGHT. He founded MATCH in 2010 to monitor viral infections in transplant patients at Rigshospitalet, now funded by a grant from the Danish National Research Foundation, it turned into a research platform across Rigshospitalet to identify factors predicting the risk of infectious complication in immune deficient patients.
Prof Jean-Michel Molina
Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, France, and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris. He received his medical degree from the University School of Medicine of Necker, Paris, and his PhD from the University School of Medicine of Bichat, Paris. Professor Molina completed his internship and residency at the Assistance Publique Hôpitaux de Paris, with a post-doctoral fellowship at Harvard University, Boston, on studies related to HIV infection of stem cells and macrophages.
Professor Molina continues to be involved in basic HIV research and is affiliated to the INSERM U941 in the Saint-Louis Hospital. As the Head of the Infectious Disease Department in the Saint-Louis Hospital, Professor Molina mainly treats immunocompromised HIV-infected patients, bone marrow and renal transplant patients, and patients with haematologic malignancies and cancers.
Professor Molina’s primary clinical research interest lies in the area of the treatment of HIV infection, and he has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 3,500 patients with HIV infection is followed in his department and is involved in this clinical research.
Professor Molina has published numerous papers in a wide variety of scientific journals, including Clinical Infectious Diseases, the Journal of Infectious Diseases, the New England Journal of Medicine, the Lancet, the Journal of Clinical Microbiology, and AIDS.
He is the Chair of the Clinical Trial Group at the French National Agency for AIDS Research (ANRS), where multicentre clinical trials are reviewed and implemented in France. Working with the ANRS, Professor Molina has been the principal investigator of a number of clinical trials in HIV-infected patients.
More recently, Professor Molina has broadened his field of interest to the prevention of HIV-infection in high risk individuals using Pre-exposure prophylaxis with TDF/FTC and has been the PI of the ANRS Ipergay trial using on demand PrEP.
